ENFN · Enfusion, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Revenue | $201.61M | $174.53M | $150.35M | $79.56M |
| Cost of Revenue | $64.87M | $57.64M | $47.10M | $21.36M |
| Gross Profit | $136.74M | $116.89M | $103.25M | $58.21M |
| R&D | - | - | - | - |
| SG&A | $78.83M | $64.64M | $68.76M | $35.89M |
| Total Operating Expenses | $130.58M | $104.95M | $115.21M | $52.13M |
| D&A | $11.75M | $9.99M | $6.34M | $2.29M |
| Operating Income | $6.16M | $11.95M | ($11.96M) | $6.07M |
| Interest Expense | - | - | - | $1.66M |
| Income Tax | $3.47M | $2.23M | $1.07M | $433.0K |
| Net Income | $2.82M | $6.03M | ($7.65M) | $4.06M |
| EPS - Basic | $0.03 | $0.07 | ($0.10) | ($2.26) |
| EPS - Diluted | $0.03 | $0.07 | ($0.10) | ($2.26) |
Balance Sheet
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Cash & Equivalents | $54.48M | $35.60M | $62.55M | $13.94M |
| Accounts Receivable | $31.99M | $28.07M | $25.86M | $12.18M |
| Inventory | - | - | - | - |
| Accounts Payable | $867.0K | $2.21M | $1.69M | $484.0K |
| Current Assets | $93.52M | $69.85M | $96.81M | $28.91M |
| Total Assets | $143.26M | $108.97M | $123.78M | $39.10M |
| Current Liabilities | $27.34M | $20.31M | $17.38M | $10.65M |
| Long-term Debt | - | - | - | $96.06M |
| Total Liabilities | $43.72M | $31.49M | $20.34M | $107.14M |
| Stockholders' Equity | $73.22M | $53.67M | $65.01M | ($233.56M) |
| Retained Earnings | ($170.11M) | ($172.93M) | ($178.86M) | ($171.21M) |
Cash Flow
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Operating Cash Flow | $34.68M | $25.63M | $14.16M | $1.67M |
| Investing Cash Flow | ($13.89M) | ($9.67M) | ($7.93M) | ($5.07M) |
| Financing Cash Flow | ($1.40M) | ($43.08M) | ($7.96M) | $11.56M |
| CapEx | $3.63M | $4.45M | $7.93M | $5.07M |
| Free Cash Flow | $31.05M | $21.18M | $6.22M | ($3.40M) |
Ratios
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Profitability | ||||
| Gross margin | 67.8% | 67.0% | 68.7% | 73.2% |
| Operating margin | 3.1% | 6.8% | -8.0% | 7.6% |
| EBITDA margin | 8.9% | 12.6% | -3.7% | 10.5% |
| Net margin | 1.4% | 3.5% | -5.1% | 5.1% |
| Free cash flow margin | 15.4% | 12.1% | 4.1% | -4.3% |
| FCF / Net income | 11.00 | 3.52 | -0.81 | -0.84 |
| R&D / Revenue | - | - | - | - |
| SG&A / Revenue | 39.1% | 37.0% | 45.7% | 45.1% |
| Effective tax rate | 55.2% | 27.0% | - | 9.6% |
| Return on assets | 2.0% | 5.5% | -6.2% | 10.4% |
| Return on equity | 3.9% | 11.2% | -11.8% | -1.7% |
| Return on invested capital | - | - | - | - |
| Liquidity | ||||
| Current ratio | 3.42 | 3.44 | 5.57 | 2.71 |
| Quick ratio | 3.42 | 3.44 | 5.57 | 2.71 |
| Cash ratio | 1.99 | 1.75 | 3.60 | 1.31 |
| Leverage | ||||
| Debt / Equity | - | - | - | -0.41 |
| Debt / Assets | - | - | - | 2.46 |
| Debt / EBITDA | - | - | - | 11.48 |
| Interest coverage | - | - | - | 3.7x |
| Equity multiplier | 1.96 | 2.03 | 1.90 | -0.17 |
| Liabilities / Assets | 0.31 | 0.29 | 0.16 | 2.74 |
| Efficiency | ||||
| Asset turnover | 1.41 | 1.60 | 1.21 | 2.03 |
| Inventory turnover | - | - | - | - |
| Days sales outstanding | 58d | 59d | 63d | 56d |
| Days inventory outstanding | - | - | - | - |
| Days payable outstanding | 5d | 14d | 13d | 8d |
| Cash conversion cycle | - | - | - | - |
| Valuation | ||||
| P / E | - | - | - | - |
| P / B | - | - | - | - |
| P / S | - | - | - | - |
| EV / EBITDA | - | - | - | - |
| Growth | ||||
| Revenue growth (YoY) | 15.5% | 16.1% | 89.0% | - |
| Revenue CAGR (3y) | 36.3% | - | - | - |
| Revenue CAGR (5y) | - | - | - | - |
| Gross profit growth (YoY) | 17.0% | 13.2% | 77.4% | - |
| Operating income growth (YoY) | -48.5% | - | - | - |
| Net income growth (YoY) | -53.1% | - | - | - |
| EPS growth (YoY) | -57.1% | - | 95.6% | - |
| EPS CAGR (3y) | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - |
| FCF growth (YoY) | 46.6% | 240.3% | - | - |
| FCF CAGR (5y) | - | - | - | - |
| Book value growth (YoY) | 36.4% | -17.4% | - | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2024-12-31.
Product / service
$201.61M totalPlatform Subscriptions$187.52M · 93.0%
Managed Services$12.69M · 6.3%
Other Services$1.40M · 0.7%
Geographic
$324.01M totalAmericas$125.80M · 38.8%
US$122.40M · 37.8%
Asia Pacific$43.46M · 13.4%
EMEA$32.35M · 10.0%
Stability scores
Altman Z′
FY 2024 · bankruptcy risk
1.57
Grey zone
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2024 · 9-point quality
5/9
Neutral
- ✓Net income positive
- ✓Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✓No share dilution
- ✓Gross margin improved
- ✗Asset turnover improved
Peer comparison
Same SIC group: Services-Prepackaged Software
Comparing Enfusion against the 5 most active filers in the same SIC group.